M&A
← 실적 발표
01
02
03
04 05 06
톤
AI
자본지출
A1 A2
IR
FY2025 Q4
예상 부합
Ingersoll Rand Inc. 실적 발표
Buzzberg 분석
M&A pipeline strong with nine LOIs and capital deployment continues
Ingersoll Rand reported Q4 2025 results with orders up 8% year-over-year (1% organic) and increased its M&A activity pipeline to 9 companies under LOI. Management issued its FY2026 guidance with 2.5-4.5% total revenue growth and $1.1 billion in recurring revenue backlog. Q4 2025 organic orders grew 1% led by China and Life Sciences; management sees flat organic growth in Q1 2026.
Buzzberg 분석 M&A pipeline strong with nine LOIs and capital deployment continues Ingersoll Rand reported Q4 2025 results with orders up 8% year-over-year (1% organic) and increased its M&A activity pipeline to 9 companies under LOI. Management issued its FY2026 guidance with 2.5-4.5% total revenue growth and $1.1 billion in recurring revenue backlog. Q4 2025 organic orders grew 1% led by China and Life Sciences; management sees flat organic growth in Q1 2026. 전체 분석 보기분석 접기
Ingersoll Rand reported Q4 2025 results with orders up 8% year-over-year (1% organic) and increased its M&A activity pipeline to 9 companies under LOI. Management issued its FY2026 guidance with 2.5-4.5% total revenue growth and $1.1 billion in recurring revenue backlog. Q4 2025 organic orders grew 1% led by China and Life Sciences; management sees flat organic growth in Q1 2026.
- FY2026 guidance expects 1% organic revenue growth at the midpoint, with M&A contributing ~1.5% and FX adding ~1%.
- Management maintains a neutral stance on macro recovery; not basing guidance on a meaningful inflection in PMI.
- Recurring revenue backlog now $1.1 billion; more confident in long-term target, though growth will be non-linear.
매출$2.0912B보고값
주당순이익(EPS)$0.96보고값
매출총이익률24.06%보고값
영업이익률31.73%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Recurring Revenue
Recurring revenue backlog reaches $1.1 billion
Guidance
Guidance implies no market recovery, with Q1 organic flat to down
핵심 내용 3개 더 보기
Guidance
2026 EPS growth expected mid-single digit across halves
Demand
Life sciences orders up mid-teens in Q4 2025
Demand
China organic orders growth for third straight quarter
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $2.0912B | 보고값 |
| 주당순이익(EPS) | $0.96 | 보고값 |
| 매출총이익률 | 24.06% | 보고값 |
| 영업이익률 | 31.73% | 보고값 |
| 잉여현금흐름 | $0.4615B | 보고값 |
| 자본지출 | $0.0375B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $3.45–$3.57 | $3.51 | 제시 |
| 영업이익률 | FY2026 | $2.13B–$2.19B | $2.16B | 제시 |
| 매출 | FY2026 | 2.5%–4.5% | 3.5% | 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Cautiously Optimisti
Management highlighted positive momentum and strong execution, but adopted a prudent approach to guidance, not baking in a market recovery.
경영진의 AI 분석
The transcript does not discuss AI, its products, demand, or adoption.
투자 및 생산능력
The transcript does not explicitly discuss capital expenditure, but management noted $525 million invested in 16 M&A transactions and $1 billion in share repurchases, indicating continued capital deployment focus.
아래에 언급된 기업 3개 모두 표시
기업발표 이후 수익률
공급망
공급망
Vicente Renal
China finished the year with a third consecutive quarter of positive organic order growth, while the rest of Asia was up mid-20s in Q4. — The persistent recovery in China and the rest of Asia, even without overall market growth, signals a competitive share shift and an improving demand environment for industrial equipment in the region.
근거
“This marks the third quarter in a row where we saw organic water growth in China, underscoring our agility through the effective use of IRX and the success of our demand generation activities delivering consistent growth in what remains a”
공급망
Vicente Renal
Life sciences organic order growth was mid-teens in Q4, while the aerospace and defense segment declined due to order timing and is expected to move sideways from 2025 to 2026. — A sideways aerospace business for IR contrasts with the strong demand from other aerospace suppliers, possibly pointing to different sub-segments or market share dynamics.
근거
“The last piece is basically the aerospace and defense business, which is down due to order timing. Nothing unexpected as the business is generally moving sideways from 2025 to 2026.”
외부 신호
공급망 알파 · 2발표 이후 수익률
China finished the year with a third consecutive quarter of positive organic order growth, while the rest of Asia was up mid-20s in Q4.
근거
“This marks the third quarter in a row where we saw organic water growth in China, underscoring our agility through the effective use of IRX and the success of our demand generation activities delivering consistent growth in what remains a…”
Life sciences organic order growth was mid-teens in Q4, while the aerospace and defense segment declined due to order timing and is expected to move sideways from 2025 to 2026.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 3개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.